Abstract
e12578Background: Chemotherapy regimens that contain both antracyclines and taxanes have been shown to increase disease free and overall survivals in patients with operable breast cancer patients. For node-positive patient group, sequential antracycline+cyclophosphamide (AC) and taxane regimen improved disease free survival (DFS) when compared with concurrent doxorubisin, cyclophosphamide and docetaxel (TAC) combination. To our knowledge, there is no data regarding the difference in between these regimens for the molecular subtypes of breast cancer. In this study we aimed to compare the clinical outcomes of triple negative breast cancer (TNBC) patients who had received adjuvant TAC versus AC followed by paclitaxel chemotherapy regimens. Methods: The files of TNBC patients were reviewed retrospectively and the demographical and clinicopathological properties of the patients and tumors were noted. The patients who had taken AC followed by paclitaxel or TAC regimens in adjuvant setting were identified and ov...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
